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 A 46-year-old female was successfuly treated with re-
peated transcatheter arterial embolization (TAE) for multi-
ple liver metastases from breast cancer. TAE using 
mitomycin C and epirubicin hydrochloride with lipiodol 
emulsion and gelatin sponge particles has been adminis-
tered to the patient eight times over 4 years. She has also 
received systemic chemotherapy. She has survived for 6 
years and 3 months after the detection of liver metastases. 
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Introduction
 Hepatic metastases has been the most life-
threatening recurrent disease in breast cancers' . 
Systemic chemotherapy or regional therapy, i. e., he-
patic arterial infusion chemotherapy and/or hepatic 
resection, have been tried for liver metastases 2 -' . 
However, no definite results of these trials have been 
reported. We herein review a case with multiple liver 
metastases from breast cancer successfully treated 
with systemic and regional chemotherapies.
Histological examination revealed an invasive ductal 
carcinoma, while a hormonal evaluation of tumor tis-
sues showed that estrogen and progesterone receptors 
were both positive. An excision of the chest wall with 
linac irradiation, a right mastectomy, and repeated 
skin excisions caused by local recurrences and metas-
tases from the left breast cancer were consecutively 
performed during the period of March 1993 and July 
1994. On September 1994, computed tomography (CT) 
initially showed multiple liver metastases, measuring 
3.5 cm (S4) and 2 cm (S3) in diameter (Fig.1), with an 
elevation of serum CA 15-3 levels (240 U/ml, normal 
range:<27 U/ml) which is an indicator of distant me-
tastases from breast cancer. Enhanced CT showed 
ring-enhancement and partly iso to low density in the 
late phase (Fig.2). Owing to the treatment with 
tamoxifen, 5-fluorouracil (5-FU) and cyclophosphamide, 
the size of liver tumors have not changed and serum 
levels of CA 15-3 ranged from 26 to 84 U/ml for one 
year and five months. CT examination showed that
Case report
 A 46-year-old female underwent a standard radical 
mastectomy for left breast cancer on September, 1989.
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Figure 1. Plain CT showed low density masses in the liver. 
arrowheads: S3, arrows: S4
Figure 2. Enhanced CT showed ring-enhancement (arrow-
heads), and iso to low enhancement (arrows) in the late phase.
Figure 4. Enhanced CT revealed strong lipiodol-deposits in 
the liver tumor after the first TAE.
Figure 3 . Selective hepatic angiography revealed diffuse 
hypervascular tumor staining.
remission or no change, and serum levels of CA 15-3 
ranged from 28 to 115 U/ml, by the 4th TAE on 
August 1997. Although the hyperbilirubinemia and 
the elevation of serum levels of CA 15-3 (195 U/ml) 
and carcinoembryonic antigen (289 ng/ml, normal 
range:<5 ng/ml) were present before the 5th TAE on 
September 1998, the bilirubin level was within the 
normal limits after the 5th TAE. Metastatic tumors 
developed in another segment of the liver after this 
time. She died on December 2000 due to the hepatic 
failure because of multiple liver metastases and an-
other recurrences such as in the pleura, the 
mediastinum, and the pericardium. She had survived 
for 58 months after the first TAE and 6 years and 3 
months after the detection of liver metastases.
metastatic liver tumor of the S4 segment had gradu-
ally increased in size, measuring about 4.5 cm in di-
ameter on December 1995. Angiography revealed dif-
fuse hypervascularity (Fig.3). The first transcatheter 
arterial embolization (TAE) using 10 mg of mitomycin 
C, 30 mg of epirubicin hydrochloride with lipiodol 
emulsion and gelatin sponge particles was performed 
on February, 1996 (Fig.4). The S4 lesion obviously de-
creased in size; however, complete remission was not 
revealed by CT examination on May 1996. We evalu-
ated that TAE was effective and that another TAE 
was necessitated for this patient. The second TAE was 
performed on June 1996. Finally, eight courses of TAE 
with the same regimen and the same doses was com-
pleted by February 2000. She also received a systemic 
treatment with aromatase inhibitor, 5-FU, and 
medroxyprogesteron which had begun on October 
1998. The size of liver tumors showed a partial
Discussion
 The results of systemic chemotherapy for hepatic 
metastases from breast cancer have been disappoint-
ing, showing a short response time in spite of high re-
sponse rates2' 4 Therefore, regional treatments have 
been proposed for improvement of survival. Hepatic 
arterial infusion chemotherapy (AI) has been per-
formed for liver metastases from breast cancer, and 
the median survival is reported to be 11 to 25.3 
months3-5,'. In our experience, AI has been performed 
in 2 patients and TAE in 3 patients. A patient with 
liver metastases solely who was treated with AI has 
survived for two years after its detection. Repeated 
TAE was performed only in this case, but there have 
been no reports of TAE therapy for liver metastases 
from breast cancer. The present patient has survived 
for 6 years and 3 months after the detection of liver
metastases, and 58 months after the first TAE, in 
spite of the presence of extrahepatic metastases. 
Among patients who received AI chemotherapy only 
about a half of them responderd and the survival 
rates of the responders were clearly superior to those 
of nonresponders, and 50% of the responders were 
alive at 18 months versus none of the nonresponders 5 . 
On the other hand, hepatic resection is considerd to be 
the best treatment for liver metastasis, if feasible. The 
median survival of hepatic resection for these condi-
tions in breast cancer, described in a few limited re-
ports, ranges from 28 to 37 months'-'. Stehlin et a15. 
emphasized that a patient who had undergone hepatic 
resection plus infusion survived the longest. It is, how-
ever, still unclear whether hepatic resection is benefi-
cial for liver metastases from breast cancer, because 
those patients also have extrahepatic metastases. 
 In conclusion, transcatheter arterial embolization 
may be an effective treatment for hypervascular 
metastatic liver tumors from breast cancer, which are 
localized solely or in a lobe of the liver.
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